$TRAX

First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics is a clinical-stage biotechnology company based in San Diego, California. It develops immunology treatments for autoimmune and inflammatory diseases in the United States. Its product candidates include ANB033, an anti-CD122 antagonist targeting a shared component of IL-15 and IL-2 receptors; Rosnilimab, an antibody designed to reduce disease-causing T cells in peripheral and inflamed tissues; and ANB101, an antibody that modulates BDCA2 to target plasmacytoid dendritic cells.

AlphAI earnings readThird Quarter 2026 · NOV 3First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $TRAX in the last 7 days.

No SEC Form 4 filings for $TRAX in the last 30 days.

See all $TRAX insider activity →
Low

First Tracks Biotherapeutics Stock Climbs Nearly 8% as Celiac Drug Hopes Push Shares Up 160% in a Year

First Tracks Biotherapeutics Inc. (TRAX) shares rose 8% to $53.57, extending a 160% year-to-date gain. The rally follows positive Phase 1b trial results for its celiac disease drug, ANB033, which showed significant protection against intestinal damage. The company has no new updates but plans late-stage development in 2027. TRAX is valued at $2.2B and reported a Q3 net loss of $31.4M.

Guggenheim raises First Tracks stock price target to $110 on celiac data

Guggenheim raised its price target for First Tracks Biotherapeutics (TRAX) to $110 from $100, citing positive Phase Ib trial results for ANB033 in celiac disease. The stock trades at $46.34 with a $1.95B market cap, though some analysts suggest it may be overvalued. The company plans further studies and presentations, with additional analyst upgrades also reported.

TRAX sentiment & insider activity

Recent TRAX coverage spans financial news, corporate actions and earnings.

What's driving TRAX

  • The stock's recent rally reflects continued optimism on ANB033, but the data have already been priced in.

    ibtimes.com.au · Nov 10, 2026

  • First Tracks Biotherapeutics, Inc. stock's average price target increased to $75 from $74.17 by 12 analysts, with a range of $57 to $110. This implies a 62% upside from the Nov. 3 closing price. All 12 analysts maintain a 'Buy' rating.

    tradingview.com · Nov 4, 2026

  • Positive trial data and higher price target suggest upside pressure on the stock.

    investing.com · Nov 4, 2026

  • Trial data suggest clinical progress, which may lift sentiment despite a modest loss.

    tradingview.com · Nov 3, 2026

  • Positive trial data and a sizable cash infusion improve First Tracks' near‑term outlook.

    SEC EDGAR 8-K · Nov 3, 2026

AlphAI scores every news story that mentions TRAX with an AI model for sentiment and relevance, and aggregates insider trades from First Tracks Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TRAX

Score

First Tracks Biotherapeutics Stock Climbs Nearly 8% as Celiac Drug Hopes Push Shares Up 160% in a Year

First Tracks Biotherapeutics Inc. (TRAX) shares rose 8% to $53.57, extending a 160% year-to-date gain. The rally follows positive Phase 1b trial results for its celiac disease drug, ANB033, which showed significant protection against intestinal damage. The company has no new updates but plans late-stage development in 2027. TRAX is valued at $2.2B and reported a Q3 net loss of $31.4M.

$TRAXHighAI 8/10Earnings

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort

First Tracks Biotherapeutics (TRAX) Reports Positive ANB033 Celiac Cohort Results

First Tracks Biotherapeutics (TRAX) reported positive Phase 1b trial results for ANB033 in celiac disease, showing significant protection against gluten-induced damage. The company expects mucosal-healing data in Q1 2027 and eosinophilic esophagitis results in Q3 2027. It also anticipates late-stage trials for celiac disease and Phase 2 trials for vitiligo in 2027. The company raised $200 million in a private placement, bringing pro forma cash to $343 million.

$TRAXMedOffering· 6.11M · closed

First Tracks Biotherapeutics, Inc. (TRAX): Entry into a Material Definitive Agreement

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 19, 2026 (the “Closing Date”), First Tracks Biotherapeutics, Inc. (the “Company”) closed its previously announced private placement (the “Private Placement”) of an aggregate 6,106,870 shares (the “Shares”) of the Co

$TRAXMedOffering· $200M

First Tracks Biotherapeutics, Inc. (TRAX): Entry into a Material Definitive Agreement

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. First Tracks Biotherapeutics Announces $200 Million Private Placement SAN DIEGO, CA — Oct. 15, 2026 — First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune a

Related tickers